Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(0.69)
# 3,982
Out of 4,531 analysts
210
Total ratings
41.7%
Success rate
-2.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Initiated Coverage: Buy | $19 | $15.19 | +25.08% | 1 | Jul 9, 2026 | |
| ANVS Annovis Bio | Initiated Coverage: Buy | $8 | $1.74 | +359.77% | 1 | Jul 9, 2026 | |
| COYA Coya Therapeutics | Maintained: Buy | $12 | $4.54 | +164.32% | 2 | Jul 6, 2026 | |
| GANX Gain Therapeutics | Maintained: Buy | $8 | $1.71 | +367.84% | 28 | Jul 1, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $9 | $3.08 | +192.21% | 19 | Jun 12, 2026 | |
| NRSN NeuroSense Therapeutics | Maintained: Buy | $3 | $0.684 | +338.60% | 6 | Jun 10, 2026 | |
| CING Cingulate | Maintained: Buy | $10 | $4.54 | +120.26% | 24 | Jun 4, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $10 | $6.89 | +45.14% | 21 | Jun 3, 2026 | |
| PYPD PolyPid | Reiterated: Buy | $9 | $5.37 | +67.60% | 18 | Jun 2, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $38 | $19.44 | +95.47% | 16 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $37 | $31.41 | +17.80% | 5 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 → $3 | $0.622 | +382.32% | 16 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $26 → $19 | $15.16 | +25.33% | 5 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 → $7 | $2.44 | +186.89% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $1 | $0.565 | +76.99% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.2828 | n/a | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8115 | n/a | 2 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.73 | n/a | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $43.54 | n/a | 9 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $31.48 | n/a | 6 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.3 | $16.28 | n/a | 5 | Sep 19, 2023 |
ProMIS Neurosciences
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $15.19
Upside: +25.08%
Annovis Bio
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.74
Upside: +359.77%
Coya Therapeutics
Jul 6, 2026
Maintained: Buy
Price Target: $12
Current: $4.54
Upside: +164.32%
Gain Therapeutics
Jul 1, 2026
Maintained: Buy
Price Target: $8
Current: $1.71
Upside: +367.84%
CervoMed
Jun 12, 2026
Reiterated: Buy
Price Target: $9
Current: $3.08
Upside: +192.21%
NeuroSense Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $3
Current: $0.684
Upside: +338.60%
Cingulate
Jun 4, 2026
Maintained: Buy
Price Target: $10
Current: $4.54
Upside: +120.26%
Entrada Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $10
Current: $6.89
Upside: +45.14%
PolyPid
Jun 2, 2026
Reiterated: Buy
Price Target: $9
Current: $5.37
Upside: +67.60%
Capricor Therapeutics
May 29, 2026
Reiterated: Buy
Price Target: $38
Current: $19.44
Upside: +95.47%
May 18, 2026
Rated: Buy
Price Target: $31 → $37
Current: $31.41
Upside: +17.80%
May 15, 2026
Reiterated: Buy
Price Target: $2 → $3
Current: $0.622
Upside: +382.32%
May 14, 2026
Rated: Buy
Price Target: $26 → $19
Current: $15.16
Upside: +25.33%
May 14, 2026
Rated: Buy
Price Target: $5 → $7
Current: $2.44
Upside: +186.89%
Apr 1, 2026
Rated: Buy
Price Target: $30 → $1
Current: $0.565
Upside: +76.99%
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.2828
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.8115
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $15.73
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $43.54
Upside: n/a
Oct 24, 2023
Maintained: Hold
Price Target: n/a
Current: $31.48
Upside: n/a
Sep 19, 2023
Reiterated: Hold
Price Target: $0.3
Current: $16.28
Upside: n/a